ABSTRACT

An accurate assessment of the recommended calcium (Ca) intake may contribute to reducing the risk of fractures and chronic diseases, ultimately improving quality of life. This review was performed to summarize key findings of Ca studies, investigate the effect of Ca intake on health outcomes, and determine the adequacy of evidence to revise the 2015 Dietary Reference Intakes for Koreans (KDRIs) for Ca in 2020. Databases were searched for intervention studies that assessed health outcomes by providing Ca in diets or as supplements. The framework of the systematic review comprised conducting literature searches, data extraction, quality assessment of the literature, and summarizing key findings relevant to set the Estimated Average Requirement (EAR) and Tolerable Upper Intake Level (UL) for Ca for the 2020 KDRI. The final search was performed in June 2019. A total of 13,309 studies were identified through databases and manual search. Sixty-five studies were included in the final quality assessment and were summarized according to health indicators. As bone health was used as an indicator of the EAR for Ca, literature reports on bone health were further categorized by the life-cycle stage of the participants. This systematic review did not find new evidence that could be applied to the general Korean adult population, including postmenopausal women, for defining a new EAR for Ca in the 2020 KDRIs. Evidence in most of the reviewed literature was considered weak; however, some evidence was found that could improve the criteria on how the EAR for Ca was determined in children and adolescents. A review of the literature for the 2020 KDRIs for Ca did not find strong evidence in order to change the recommended values of the 2015 KDRIs. More clinical interventions are required among Koreans to strengthen the body of evidence to warrant the revision of the KDRIs.

Keywords: Calcium; Dietary Reference Intakes for Koreans; bone; adolescents; review

INTRODUCTION

Calcium (Ca) makes up almost 40% of the total mineral mass in the human body. Over 99% of total body Ca is stored in the skeleton and teeth as hydroxyapatite, where it provides structural support [1]. The remaining 1% is freely available in the serum, extracellular
fluid, and soft tissues [1]. Serum Ca is tightly regulated, and the body uses bone tissue as a reservoir to maintain constant concentrations of Ca in the serum, muscle, and intercellular fluids [1]. Adequate Ca intake is beneficial to bone health and possibly in the prevention of other chronic diseases, such as obesity, cancer, and cardiovascular disease [2].

The 2015 Dietary Reference Intakes for Koreans (KDRIs) for Ca was based on the effect of adequate intake on bone health owing to the limited number of studies on other health outcomes. In 2015, Ca equilibrium, bone mineral density (BMD), and fracture risk were used as major health indicators in the literature review to establish the Estimated Average Requirement (EAR) for Ca. The EAR and Recommended Nutrient Intake (RNI) for Ca were calculated using the average body size and mean Ca absorption rate of Koreans by the life-cycle stage. However, the reference body weight in some age groups was underestimated. In addition, until the revision of the 2015 KDRIs, the basis for recommendations, such as Ca accumulation during growth and Ca absorption, were mostly based on studies conducted among non-Asians. Therefore, in 2020, we focused on investigating various health outcomes associated with Ca intake and improving the 2020 KDRIs for Ca to better reflect Korean or at least Asian characteristics.

The main questions of the literature review regarding the revision of KDRIs for Ca in 2020 are as follows.

1) Does adequate evidence exist to revise the recommendations for Ca in the 2020 KDRIs?
2) Is there sufficient evidence for the necessary Ca intake through food or supplements related to disease prevention other than bone health indicators?

SEARCH METHODS FOR THE IDENTIFICATION OF STUDIES

Data source and literature search

Electronic databases were systematically searched according to Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA) guidelines [3]. Further search of the MEDLINE, EMBASE, and Web of Science, from January 2008 until June 2019 were performed. To search for literature reporting the data from Korean participants, additional searches of the Korean Studies Information Service System (KISS), National Digital Science Library (NDSL), DBpia, and Research Information Sharing Service (RISS) were performed. The search terms, which were based on the EAR and Tolerable Upper Intake Level (UL) for Ca, consisted of the Ca type and its synonyms (“calcium,” “calcium carbonate,” “dietary calcium,” “dairy product,” “calcium citrate,” “calcium phosphates,” “calcium malate”); health outcomes for setting the EAR (“cardiovascular disease,” “hypertension,” “pregnancy related non-skeletal disorders,” “bone health,” “growth,” “cancer,” “obesity,” “type 2 diabetes,” “metabolic syndrome,” “frailty,” “sarcopenia,” “mortality”); and health outcomes for setting the UL (“kidney stones,” “heterotopic and ossification,” “bone health,” “calcinosis,” “hypercalcemia,” “calculus”). The search terms related to the abovementioned outcomes were listed in Supplementary Tables 1 and 2. MESH terms and subject headings were used in coordination with each database’s rules. The same English search terms and additional Korean language terms, related to Ca balance and bone health, were applied to the Korean search engines: KISS; NDSL; DBpia; and RISS. Additionally, relevant Korean journals, including the Journal of Bone Metabolism, Journal of Korean Society of Food Science and Nutrition, and non-DB indexed issues of the Journal of Nutrition and Health, were hand-searched.
Study selection
The inclusion criteria were as follows: (1) studies performed only in healthy participants or participants with less than 20% of the study population (except for studies in adults aged 65 yrs and older); (2) interventions of dairy products, Ca supplements, or Ca and vitamin D supplements; (3) the study design was an intervention, prospective cohort, or nested case-control; and (4) cross-sectional studies and case-control studies in Asians were included due to the limited number of intervention studies in Asians. The following exclusion criteria were applied: (1) animal or cell studies; (2) conventional review paper; (3) meta-analyses; (4) studies in participants where over 20% had a disease; (5) interventions with nutrients other than Ca and vitamin D; (6) interventions where the Ca supplemented group served as control; (7) cross-sectional or case-control studies in non-Asians; (8) non-English or Korean language; and (9) unpublished data (e.g. scientific meeting abstract). Afterwards, duplicate and non-relevant studies were excluded. Abstract screening was performed with Rayyan by 3–4 research staff under the supervision of CYP and KK between 2014–2019, and independently by MJC and SYB between 2008–2013. Full-text evaluation was performed by 3–4 research staff under the supervision of CYP and KK between 2014–2019 and by MJC and SYB between 2008–2013 and disagreements were primarily resolved through discussions among the authors. We could not perform any quantitative data analysis because our search identified only a few studies by distinguished life-cycle stages and was thus inadequate to perform a meta-analysis.

Quality assessment and result summary
Quality assessment tools were applied in the systematic review for exploring scientific basis of the revision of KDRI for Ca depending on the study design, study population, risk of bias, and result consistency. The Strengthening and Reporting of Observational studies in Epidemiology (STROBE) statement [4] was used to assess the quality of cross-sectional studies. For cohort studies including nested case-control and case-control studies, the Newcastle-Ottawa scale [5] was applied. For assessment of intervention studies, the Jadad scale [6] was used. In conjunction with quality assessment, study findings were summarized in a specific table to identify feasible evidence for the revision of the 2020 KDRI for Ca.

RESULTS

Results of the systematic review for establishing the EAR for Ca
From literature published between January 2014 and June 2019, the initial database search identified 13,246 articles. After duplicates were removed, we screened 9,878 articles. The included articles were randomized controlled trials (RCTs), intervention studies, or cross-sectional studies (in Asians only) that provided information on the dose of Ca, dietary Ca intake, and Ca status of the study participants. Fifty-nine publications fulfilled the inclusion criteria for performing the quality assessment. In an additional literature search of the Korean databases and literature published between 2008 and 2013, a total of 63 articles were identified of which 6 articles were subjected to sequential review. A total of 65 studies were included in the review. The study selection process is illustrated in Fig. 1.

Characteristics and main findings of the included studies according to bone health indicators
Results of individual studies from the literature assessment have been outlined in Tables 1-3 according to the health indicators for setting the EAR and UL for Ca. For the bone health
## Table 1. Characteristics of the included studies examining the effect of Ca intake (EAR level) on bone health of infants, children, and adolescents aged 0 to 18 yrs (RCTs)

| Author               | Study design | Treatment for RCTs/ Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed               | Risk of bias |
|----------------------|--------------|--------------------------------------------------------|-----------------------------|--------------|--------------------------------|--------------|
| Vogel et al. (2017, US) [11] | RCT-parallel | Supplement group: 3 servings/d of dairy products (about 900 mg of Ca) vs. Usual diets | Healthy children (n = 112) 18 mon BMC, BMD, BMA (whole body) | High         |
| Roeze et al. (2016, Tibet) [7] | RCT-parallel | Ca + vitamin D group: 600 mg/day\(^2\) Ca + 25,000 IU/month vitamin D vs. Ca group: 600 mg/day\(^2\) Ca vs. Vitamin D group: 25,000 IU/mon vitamin D vs. Control | Infants (n = 207): 2.5 yrs Range: 0–5 yrs | Dental health | High |
| Ward et al. (2014, Gambia) [8] | RCT-parallel | Ca group: 1,000 mg of Ca carbonate vs. Placebo | Boys (n = 80): 9.95 yrs Age range: 8–11.9 yrs | BMC, BMA (whole body, lumbar, total hip) | Low |
| Palacios et al. (2014, US) [9] | RCT-parallel | Low Ca group: 631–1,275 mg High Ca group: 1,118–2,157 mg | Mexican-American adolescents Boys (n = 20): 14.1 ± 0.9 yrs Girls (n = 20): 13.6 ± 1.0 yrs | Ca retention, urinary, and fecal Ca excretion | Low |
| Ma et al. (2014, China) [10] | RCT-parallel | Low Ca group: 40 g milk powder + 200 IU vitamin D (total Ca: 300 mg) vs. Medium Ca groups: 40 g milk powder + 300 mg Ca + 200 IU vitamin D (total Ca: 600 mg) vs. High Ca group: 40 g milk powder + 600 mg Ca + 200 IU vitamin D (total Ca: 900 mg) | Boys (n = 109): 12.9 ± 0.3 yrs Girls (n = 112): 13.0 ± 0.4 yrs | BMC, BMD (whole body, spine, left hip, femoral neck) | Low |

Ca, calcium; EAR, estimated average requirement; RCT, randomized controlled trial; BMC, bone mineral content; BMA, bone mineral area; BMD, bone mineral density.

1The quality of each study was assessed on the basis of the study design, and risk of bias assessment was used for RCTs [6];
2Ca of 15 mmol and vitamin D of 625 μg were given to the study participants. The mmol unit of Ca and μg of vitamin D are converted to mg and IU in the table, respectively.

---

**Fig. 1.** Flow chart of study selection in the systematic review for the 2020 KDRIs for calcium.

**KORI, Dietary Reference Intakes for Korean; KISS, Information Service System; NDSL, National Digital Science Library; RISS, Research Information Sharing Service.**

**1**Since search terms applied for the 2015 KDRIs (publications years 2008–2013) differ from that for the 2020 KDRIs (publications searched for years 2014–2019), an additional database search was performed for studies published between years 2008 and 2013 to apply the same search terms as 2014–2019 publications for bone health.
Table 2. Characteristics of the included studies examining the effect of Ca intake (EAR level) on bone health of adults aged 19 yrs and older

| Author | Year, Country | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|--------|---------------|-------------|-------------------------------------------------|-----------------------------|-------------|-----------------|-------------|
| Zenk et al. | 2018, US | RCT-crossover | Ca group 1: 720 mg of Ca Aquamin F™ vs. Placebo; Ca group 2: 720 mg of Ca carbonate vs. Placebo | Twelve fasting women (n = 12); Mean age: 28.8 yrs | Single oral supplement intervention; Cross-over manner with 7-days wash-out period between treatments | Serum PTH and ionized Ca at 90, 120, and 240 min after single treatment | Low |
| Silk et al. | 2017, Australia | RCT-parallel | Ca + vitamin D group: 800 mg of Ca + 400 IU of vitamin D vs. Placebo | Jockeys (n = 17); Ca + vitamin D group (n = 8): 22.3 ± 5.0 yrs; Placebo group (n = 9): 19.3 ± 1.8 yrs | 6 mon | PQCT of the ultra-distal (4%) and proximal (66%) radius at baseline and 6 mon. Serum vitamin D, P1NP, and CTX | Some concerns |
| Liu et al. | 2015, China | RCT-parallel | Ca + vitamin D group: 1,500 mg of Ca + 200 IU of vitamin D vs. Exercise + Ca + vitamin D group vs. Exercise group vs. Control group | Postmenopausal women aged 50–75 yrs-outpatients in a hospital in China (age-matched); Ca + vitamin D group (n = 45); Exercise + Ca + vitamin D group (n = 49) | 12 mon | BMD in the lumbar spine and femoral neck | High |
| Mathis et al. | 2015, UK | RCT-parallel | Ca group: 1,071.8 mg vs. Control group: 1,246.3 mg | Men cyclists (n = 17); Ca group (n = 9): 43.3 ± 11.5 yrs; Control group (n = 8): 41.9 ± 12.0 yrs | 5 mon | Areal BMD in the hip, lumbar spine, femoral neck, femoral trochanter | High |
| Silk et al. | 2015, Australia | RCT-parallel | Ca + vitamin D group: 800 mg of Ca + 400 IU of vitamin D vs. Placebo | Jockeys (n = 17); Ca + vitamin D group (n = 8): 22.3 ± 5.0 yrs; Placebo group (n = 9): 19.3 ± 1.8 yrs | 6 mon | Trabecular BMA, BMC, and bone strength Cortical BMA, thickness, BMC, and bone strength | Low |
| Gaffney-Stomberg et al. | 2014, US | RCT-parallel | Ca + vitamin D group: 2,000 mg of Ca + 1,000 IU of vitamin D vs. Placebo | Men (n = 156) and women (n = 87) in initial army training; Ca + vitamin D group (n = 25): 21.4 ± 3.8 yrs; Placebo (n = 21): 21.4 ± 3.7 yrs | 9 wks | PQCT of the tibia bone density and strength Serum vitamin D and PTH | Low |
| Slevin et al. | 2014, UK | RCT-parallel | Ca group: 800 mg of Ca vs. CaFOS group: 800 mg of Ca + 3.6 g of scFOS vs. MD group: 9 g of MD | Postmenopausal women aged 45–75 yrs; Ca group (n = 100): 61.3 ± 6.6 yrs; CaFOS group (n = 100): 61.3 ± 6.4 yrs; MD group (n = 100): 60.4 ± 6.3 yrs | 2 yrs | BMD in the lumbar spine, femoral neck, and whole body Serum Ctx, osteocalcin | Some concerns |
| Aloia et al. | 2013, US | RCT-parallel | Ca + vitamin D group: 1,200 mg of Ca + 100 µg vitamin D vs. Ca group vs. Vitamin D vs. Placebo | White postmenopausal women; Ca + vitamin D group (n = 46): 57.6 ± 7.1 yrs; Placebo (n = 31): 58.6 ± 6.7 yrs | 6 mon | Serum PTH, CTX, and P1NP | Low |
| Rajatanavin et al. | 2013, Thailand | RCT-parallel | Ca group: 500 mg of Ca vs. Placebo | Postmenopausal women aged 65.8 ± 4.4 yrs | 2 yrs | BMD in the lumbar spine and femoral neck Serum vitamin D, CTX Plasma PTH | Low |
| Nakamura et al. | 2012, Japan | RCT-parallel | Ca group 1: 500 mg of Ca vs. Ca group 2: 250 mg of Ca vs. Placebo | Women aged 50–75 yrs; Ca 500 mg group (n = 142): 59.2 ± 5.9 yrs; Ca 250 mg group (n = 139): 60.3 ± 6.1 yrs; Placebo (n = 137): 59.5 ± 5.6 yrs | 2 yrs | BMD in the lumbar spine and femoral neck Serum vitamin D, CTX, osteocalcin | Low |
| Aloia et al. | 2010, US | RCT-parallel | Ca + vitamin D group: 1,200 mg of Ca carbonate + 100 µg vitamin D vs. Ca group: 1,200 mg of Ca vs. Vitamin D vs. Placebo | Men and women, aged 20–80 yrs; Ca + vitamin D group (n = 25): 56.5 yrs; Ca group (n = 21): 55.1 yrs; Vitamin D group (n = 25): 53.1 yrs; Placebo (n = 23): 54.8 yrs | 3 mon | BMD in the hip, spine, and whole body | Low |

(continued to the next page)
Table 2. (Continued) Characteristics of the included studies examining the effect of Ca intake (EAR level) on bone health of adults aged 19 yrs and older

| Author et al. | Year, Country | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|---------------|---------------|--------------|-------------------------------------------------|-----------------------------|-------------|-----------------|-------------|
| Reid et al.   | 2008, US      | RCT-parallel | Low supplement Ca group: 600 mg of Ca vs. High supplement Ca group: 1,200 mg of Ca vs. Placebo | Men aged 40 yrs and older: 600 mg Ca (n = 101): 55 ± 10 yrs; 1,200 mg Ca group (n = 102): 57 ± 10 yrs; Placebo (n = 103): 57 ± 10 yrs | 2 yrs | BMD in the lumbar spine, hip, and whole body | Low |
| Chinda et al. | 2019, Japan   | Cross-sectional | Ca intake level ≥ 650 mg Ca vs. < 650 mg Ca | Men aged 19 yrs and older: (49.1 ± 15.1 yrs) ≥ 650 mg/day Ca (n = 54) vs. 650 mg/day Ca (n = 214) | End point measurement | Event in osteopenia and odds ratio | Low |
| Alghadir et al. | 2015, Saudi Arabia | Cross-sectional | Ca intake level vs. < 400 mg/day Ca vs. 400–800 mg/day Ca | Men and women aged 20–40 yrs: Group 1 (25–30 yrs; n = 186; 100 men and 86 women) vs. Group 2 (31–45 yrs; n = 164; 60 men and 104 women) | End point measurement | Lumbar spine, and total and femoral neck BMD | Some concerns |
| Lee et al. | 2015, Korea | Cross-sectional | Ca + vitamin D group: history of receiving 500 mg of Ca supplement as CaHPO4 + 500 IU vitamin D vs. Control group | Men (n = 1,096): 63.2 ± 8.7 yrs vs. Women (n = 844): 62.9 ± 9.8 yrs | End point measurement | BMD in the lumbar spine and femoral neck | Some concerns |
| Samozai et al. | 2015, India | Cross-sectional | Ca + vitamin D group: history of receiving 500 mg of Ca supplement as CaHPO4 + 500 IU vitamin D vs. Control group | Postmenopausal women aged 48–60 yrs: outpatients of orthopedics who already received Ca supplements with vitamin D from the hospital’s pharmacy for up to 12 mon Ca + vitamin D group (n = 30) vs. Control group (n = 30) | End point measurement | Lumbar spine, and total and femoral neck bone BMD | Some concerns |
| Kim et al. | 2014, Korea | Cross-sectional | Ca intake level < 400 mg Ca vs. 400–799 mg Ca vs. 800–1,199 mg Ca vs. ≥ 1,200 mg Ca | Men and women aged 50 yrs and older: (participants in the 2008–2011 KNHANES) 400 mg/day Ca (n = 3,745) vs. 400–799 mg/day Ca (n = 2,572) vs. 800–1,199 mg/day Ca (n = 687) vs. ≥ 1,200 mg/day Ca (n = 256) vs. ≥ 1,200 mg/day Ca (n = 256) | End point measurement | BMD in the total hip, lumbar spine, and femoral neck Serum vitamin D and PTH | Low |
| Lee et al. | 2014, Korea | Cross-sectional | Ca intake level | Men: Men ≤ 50 (n = 1,405): 30.4 ± 0.3 yrs vs. Men ≤ 50 (n = 904): 61.3 ± 0.4 yrs Women: Premenopausal women (n = 1,758): 30.5 ± 0.3 yrs vs. Postmenopausal women (n = 868): 62.9 ± 0.5 yrs | End point measurement | BMD in whole body, lumbar spine, and femoral neck | Low |
| Lee et al. | 2014, Korea | Cross-sectional | Ca intake level | Old adults: Men (n = 1,374): 71.7 ± 0.2 yrs vs. Women (n = 1,569): 72.7 ± 0.2 yrs | End point measurement | BMD in the lumbar spine, total femur, and femoral neck | Some concerns |
| Yang et al. | 2014, Korea | Cross-sectional | Ca intake level | Middle-aged and older men (n = 2,305): Age range: 50–79 yrs | End point measurement | BMD in whole body, lumbar spine, total femur, and femoral neck | Low |
| Lee and Choi | 2013, Korea | Cross-sectional | Ca intake level | College women students at Daegu, Korea (n = 83): 22.8 ± 5.4 yrs | End point measurement | Calcaneus BMD | Low |

Ca, calcium; EAR, Estimated Average Requirement; Aquamin F™, botanical Ca derived from the marine algal Lithothamnion sp.; BMA, bone mineral area; BMC, bone mineral content; BMD, bone mineral density; PINP, procollagen type 1 N propeptide; CTX, C-terminal cross-linked telopeptide of type I collagen; KNHANES, Korea National Health and Nutrition Examination Survey; PTH, parathyroid hormone; pQCT, peripheral Quantitative Computed Tomography; scFOS, short-chain fructo-oligosaccharide; RCT, randomized controlled trial; CaFOS, 800 mg of calcium with 3 g of short-chain fructo-oligosaccharide; MD, maltodextrin.

1) The quality of each study is assessed on the basis of the study design, and risk of bias assessment is used for RCTs [6] or cross-sectional studies [4].
Results of studies in infants aged 0 to 12 mon

In the study of infants, only one RCT study, which measured the tooth loss incidence and growth bone index was reviewed [7]. The study followed up on Tibetan children aged 0–5 yrs for 3 yrs, who received either Ca (15 mmol/day, equivalent to 600 mg/day), with or without vitamin D (625 μg/mon), or no supplement and found no significant improvement in growth and bone metabolism (Table 1). The evidence on the effect of Ca supplementation on bone health indicators in infants was limited.

Results of studies in children and adolescents aged 1 to 18 yrs

Four RCTs studies were reviewed for children and adolescents to examine the relationship between Ca intake and growth, and bone health indicators (Table 1). Gambian boys received 1 yr of Ca carbonate supplementation (1,000 mg/day), which advanced their growth spurt but had no lasting effect on bone mineral or bone size [8]. Ca retention in Mexican-American adolescents increased with Ca intake (P < 0.0001) ranging from 600 to 2,200 mg/day but did not differ by sex (P = 0.66) [9]. When Chinese adolescents aged 12–14 yrs were given 300, 600, and 900 mg of Ca supplements for 1 yr (total Ca intake including meals, 700 mg, 900 mg, and 1,300 mg), the femoral neck bone mineral content (BMC) increased regardless of sex. However, there was no significant difference between the 900 mg and 1,300 mg total Ca intake groups [10]. In the Unites States (US), white and black adolescents aged 8–16 yrs were classified based on body weight into healthy weight group (50–70 percentile), overweight group (85 percentile or more), and allocated to a supplement group (900 mg Ca/day per day for the healthy weight group, and 1,500 mg Ca/day for the overweight group). The results showed that supplementation with Ca increased bone mineral density (BMD) and bone mineral area (BMA) in both groups, but the effect was more pronounced in the overweight group. The evidence on the effect of Ca supplementation on bone health indicators in children and adolescents aged 1 to 18 yrs was limited.
through 3 servings of dairy products) or control group. Bone indicators were observed every 6 mon for 18 mon, and the bone content of the tibia increased by 4% in the supplement group; however, there was no significant difference regarding other bone indices [11].

The current recommended Ca intake in Korea is 1,000 mg and 900 mg for boys, and 900 mg and 800 mg for girls aged 12–14 yrs and 15–18 yrs, respectively [12]. The results of reviewed studies suggested that Ca supplementation in children and adolescents would be helpful in accumulating bone mass, but the amounts of Ca intake reported in these studies to increase bone accumulation were not different from the Ca requirement stated in the 2015 KDRIs calculated based on the physical growth standard. Therefore, there was no evidence to warrant reduction or increment of the currently applied Ca intake in children and adolescents.

**Results of studies on men aged 19 yrs and older, and young women**

Of the literature evaluated regarding bone health indicators including BMD, BMC, bone mineral area (BMA), and serum metabolites in adults, eleven studies were 2-armed RCTs [13-23], and one was a cross-over study [24]; 5 of the studies were from the US, 2 from the United Kingdom (UK) [16,20], 2 from Australia [13,18], one from China [19], one from Japan [23], and one from Thailand [25]. Ten studies were cross-sectional [25-34], of which 7 were from Korea [25,27,30,32,33], one from Japan [26], one from Saudi Arabia [34], and one from India [31] (Table 2).

A total of 7 RCT studies reported findings for adult men and young women. In a study conducted with healthy young Australian jockeys in their twenties, Ca supplementation of 800 mg and 400 IU vitamin D for 6 mon significantly increased BMC (6.6%), BMA (5.9%), and BMD (1.3%) in the proximal cortical bone of the tibia; however, these changes were not significantly different from the placebo-control group [12,13]. The group supplemented with the same amount of Ca and vitamin D had shown higher vitamin D levels (18.1%, \( P = 0.014 \), partial \( \eta^2 = 0.38 \)) and lower C-terminal cross-linked telopeptide of type I collagen (CTX) (−24.8%, \( P = 0.011 \)), but there was no difference in either trabecular or cortical bone properties between groups [18]. In a study with male and female military personnel (mean age, 21.4 yrs) Ca supplementation with 2,000 mg and 1,000 IU vitamin D increased serum Ca levels, BMD, BMC, and thickness of the cortical bone by 14% in both groups [17]. Ca consumption of 1,600 mg and 1,000 IU of vitamin D prior to cycling for 5 mon did not ameliorate the negative effects of competitive cycling on the hip BMD in male road cyclists [16]. Overall, the findings regarding the change in bone health indicators in response to Ca supplementation are inconsistent. In addition, participants in the aforementioned studies, such as athletes and soldiers, are under repetitive physical loading [13,17,18]; therefore, the results may not apply to general adults whose physical activity strength is weak or moderate. In 2 additional reviewed RCTs reported during 2008–2013, healthy men in the US (mean age, 57 yrs) who consumed 600 mg or 1,200 mg of Ca have shown an increased level of serum alkaline phosphatase, a bone formation indicator, and a decreased level of CTX, a bone resorption marker, in a dose-dependent manner compared to those in the placebo group. However, BMD was found to increase by 1.0–1.5% only in a group of participants who consumed 1,200 mg of Ca [15]. Ca supplementation with 1,200 mg for 3 mon decreased the serum bone resorption marker in healthy adult men and women in the US population (age range, 20–80 yrs old) [14]. An RCT conducted with healthy women (mean age, 28.8 yrs) reported increased parathyroid hormone (PTH) level after commercially manufactured Ca supplementation. However, this study only performed a single time point of Ca supplementation in participants with obesity (body mass index [BMI] > 25.5), and their sodium intake was limited to < 100 mEq [24] indicating that this evidence would be ineligible for extrapolation regarding the level of Ca consumption from the daily diet.
A total of 9 cross-sectional studies were reviewed to explore evidence in setting the EAR for Ca in adult men and young women. Of the study results reported, Japanese men who consumed Ca < 650 mg/day have shown a 2.92-fold higher risk of osteopenia than men who took Ca ≥ 650 mg/day (95% confidence interval, 1.09–7.81) [26]. A study on Korean men (aged < 50 yrs) reported a positive association between Ca intake and BMD in the femoral neck and lumbar spine [25,27-29], while no significant association was observed in men aged ≥ 50 yrs [28]. A study conducted in Daegu, a metropolitan city in Korea, reported that Ca intake in young Korean female college students (mean age, 22.8 yrs old; mean BMI, 21.8) was only 77% of the RNI [30]. This study also reported that the mean Ca intake was 568.9 mg in students of the normal BMD group and 446.2 mg in students of the osteopenia group without significant difference in energy consumption between the groups [30], indicating a positive relationship between Ca intake and Ca accretion in young women. The levels of Ca used in these studies are mostly in the range of the EAR for Ca in the 2015 KDRI [12].

**Results of studies on postmenopausal women aged 50–75 yrs**

In finding evidence in postmenopausal women, 5 RCTs and 4 cross-sectional studies were reviewed. Postmenopausal women aged 50–75 yrs who participated in the program of exercise (“the modified eighth section of the Eight-Section Brocade”) with 500 mg of daily Ca intake for 12 mon have shown increased lumbar spine BMD compared to women in a group only receiving Ca supplement without physical activity [19]. However, the study did not assess the amount of Ca obtained from the participants’ daily diet; hence, the exact amount of total Ca intake could not be inferred. Additionally, the effect of Ca on bone indicators could not be distinguished from the effect of physical activity. In women aged 45–75 yrs who were residing in the Ulster area in the UK, Ca intake of 900 mg/day for 1 yr did not induce any change in bone parameters in the lumbar spine and femoral neck during the 1-yr follow-up period [20]. Ca supplementation with 1,200 mg/day for 3 mon decreased the serum CTX, bone resorption marker, and PTH level in response to instant Ca load in healthy postmenopausal white American women [21]. However, the level of Ca effective in bone metabolism indicators reported in Asian countries are uncertain because the study participants’ basal Ca intake is different per study or not reported. A study conducted in Thailand reported that approximately 800 mg/day of Ca intake including the dietary Ca for 2 yrs increased the lumbar BMD by 2.7% compared to baseline measurement in healthy Thai postmenopausal women whose average daily Ca intake is 376 mg [22]. In a study conducted with Japanese postmenopausal women aged 50–75 yrs, Ca supplements of 500 mg/day slowed bone loss in the lumbar spine and femoral neck during a 2-yr follow-up period in perimenopause and postmenopausal women with a habitually low Ca intake (< 500 mg/day) [23]. Indian postmenopausal women, outpatients of orthopedics, who had a history of receiving tablets containing 500 mg Ca and 500 IU vitamin D for at least a month up to 12 mon have shown an increased urinary Ca excretion without the change in the serum Ca level, indicating enhanced Ca retention [31].

In the Korea National Health and Nutrition Examination Survey (KNHANES) conducted on the Korean population, Ca intake was positively correlated with the whole-body BMD in premenopausal women, while no significant association was detected in postmenopausal women aged ≥ 50 yrs [25,27,28]. Another study, which analyzed the data from the 2008–2011 KNHANES, reported the association between Ca intake and the risk of metabolic syndrome and BMD [32]. In this study, participants were categorized by their daily Ca intake amount: < 400 mg; 400–800 mg; 800–1,200 mg; and ≥ 1,200 mg. Increased lumbar and femoral BMD and decreased odds ratio for the risk of osteoporosis were reported in groups with a Ca intake of 400–800 mg. Position statements of the 2015 Korean Society for Bone and Mineral Metabolism (KSBMM) recommended a daily Ca intake of 800–1,000 mg/day for
preventing and treating osteoporosis in Korean postmenopausal women and men aged ≥ 50 yrs [35]. In the 2015 KDRIs, an extra 100 mg/day of Ca was added to the calculated RNIs for postmenopausal women as a reasonable margin of safety for lessening bone loss due to the typically low Ca intake of Korean women and need for public health protection at this life stage [12]. Postmenopausal women have a particularly higher risk of fracture, which may be exacerbated with inadequate Ca intake. Observational studies in Koreans indicate that adults with dietary Ca intakes over 668 mg/day have lower PTH and higher BMD at the femoral neck and spine [36], whereas others show that dietary intake of 800 mg/day and above is associated with better bone health despite adequate D status [33]. However, Ca intake through supplements was not accounted for in these studies. Nevertheless, these intakes are similar to the requirements calculated from a balance study in Japanese older adults [37].

In the literature reviewed in assessing the EAR for Ca in adults, findings from the RCTs were inconsistent due to different study conditions. Study participants under atypical physical activity were included, such as cyclists, soldiers, and jockeys, and the use of a broad range of Ca doses. Furthermore, inferring the proper Ca level, which may be advantageous to bone health outcomes on the data from Asian countries appears unreliable in Korean adults because the basal Ca intake of study participants varies per studies, and the Ca absorption data specific in the Korean population is almost scarce. Hence, the results achieved before June 2019 are not applicable to the general Korean adult population, including postmenopausal women in the 2020 KDRI.

Results of studies in pregnant or lactating women
In terms of the evidence in pregnant or lactating women, a total of 5 RCT studies were reviewed (Table 3). In Brazilian adolescent mothers who received Ca (600 mg/day) plus cholecalciferol (200 IU/day) supplementation or placebo from 26 wks of gestation to parturition, the BMC, BMD, and bone area BA changes in infants born were not different between supplementation and placebo group. However, infant body weight and its increment were higher in the supplemented group [38]. Another study of pregnant adolescents in Brazil aged 13–19 yrs reported that changes in bone mass by Ca supplementation were dependent on the genotype of the vitamin D receptor (VDR) [39]. In a study of short-term interventions in adult pregnant women, participants in their first trimester of pregnancy who received either 1,200 mg/day Ca or placebo were followed through 1-mon postpartum. Ca excretion in the Ca supplement group decreased by 15.8% on average, as compared to the placebo group, but there was no significant effect of Ca on bone formation. However, in participants who consumed 50% or more of the prescribed Ca, the bone speed of sound in the arm bone, which is an index of increase in bone thickness, increased by 59.0 m/s (P = 0.009) at 1 mon after childbirth [40]. In White and Black American pregnant women aged 19–50 yrs who received 1,000 mg of Ca and 2,000 IU of vitamin D for 36 mon, the supplement group had significantly greater increases in radial total BMD (P = 0.02) and tibial cortical BMD (P = 0.03) at 12 mon postpartum than the placebo group [41]. In Chinese postpartum lactating women, change in BMD from baseline to 12 mon among the 3 groups of 300 mg Ca (40 g milk powder), 600 mg Ca (40 g milk powder and 300 mg Ca supplement), and 900 mg Ca (40 g milk powder and 600 mg Ca supplement) was not significantly different [42].

Overall, the evidence on the effect of Ca supplementation on bone health indicators in pregnant or lactating women was limited or inconsistent. The results showed that the positive changes in bone health indicators after Ca supplementation during pregnancy and lactation were not significant.
Characteristics and main findings of studies according to health outcomes other than bone

The main findings of the studies extracted through the search of keywords related to health outcomes other than bone health in setting the EAR for Ca were summarized in Tables 4–7. Other health outcomes included growth (5 RCTs, 2 cohort, and one nested case-control), cardiovascular disease (7 RCTs and 2 cross-sectional), hypertension (3 RCTs and 3 cohort), obesity, diabetes, and metabolic syndrome (4 RCTs, 6 cohort, and one cross-sectional) cancer (one RCTs and one cohort), frailty & sarcopenia (2 RCTs). Overall, reviews of cancer, frailty and sarcopenia among non-bone health outcomes were excluded because of a small number of studies reviewed in this study.

### Table 4. Characteristics of the included studies examining the effect of Ca intake (EAR level) on growth

| Author (Year, Country) | Study design | Treatment for RCTs/ Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias1) |
|------------------------|--------------|--------------------------------------------------------|-----------------------------|--------------|-----------------|---------------|
| RCTs                   |              |                                                        |                             |              |                 |               |
| **Tablet**             |              |                                                        |                             |              |                 |               |
| Rooze et al. (2016, Tibet) [7] | RCT-parallel | Ca + vitamin D group : 600 mg/day6 Ca + 25,000 IU/ month vitamin D vs. Ca group : 600 mg/day6 Ca vs. Vitamin D group : 25,000 IU/month vitamin D vs. Control | Tibet children (n = 207): 2.5 yrs Age range: 0–5 yrs | 3 yrs | KBD, rickets | High |
| Asemi et al. (2016, Iran) [43] | RCT-parallel | Ca + vitamin D group : 500 mg Ca + 200 IU cholecalciferol vs. Placebo | Newborns (first 24 h after birth) of Iranian pregnant women (n = 42) Age range (pregnant women): 18–40 yrs | 9 wks | Weight, length, head circumference | Low |
| Diogenes et al. (2015, Brazil) [38] | RCT-parallel | Ca + vitamin D group : 600 mg Ca + 200 IU cholecalciferol vs. Placebo | Brazilian pregnant adolescents (n = 56): 16 yrs Age range: 13–19 yrs Ca + vitamin D group (n = 30): 16.8 ± 1.5 yrs Placebo group (n = 26): 17.2 ± 1.0 yrs Newborns at 5 wks postpartum | 5 wks at postpartum | Weight, length, head circumference | Some concerns |
| Khadilkar et al. (2014, India) [44] | RCT-parallel | Ca + vitamin D group : 500 mg/day Ca + 30,000 IU/3 mon vitamin D vs. Control | Premenarchal girls (n = 119) Age range: 8–12 yrs Ca + vitamin D group: Baseline 10.1 ± 1.5 yrs End line 11.3 ± 1.5 yrs Control: Baseline 10.1 ± 1.5 yrs End line 11.2 ± 1.5 yrs Newborns at 5 wks postpartum | 1 yr | Height velocity, height-for-age Z-score, weight-for-age Z-score, BMI-for-age Z-score | Low |
| Ward et al. (2014, Gambia) [8] | RCT-parallel | Ca group : 1,000 mg Ca carbonate (5 d/wk) vs. Placebo | Gambian boys (n = 80): 9.95 yrs Age range: 8–11.9 yrs | 12 yrs | Lean mass (whole body) | Low |
| Nested case-control or cohort studies |              |                                                        |                             |              |                 |               |
| Tuokkola et al. (2017, Finland) [45] | Nested case-control | Elimination of cow's milk | Children (n = 560); ≤ 5 yrs CM elimination diet only (n = 90) WBR elimination diet only (n = 75) CM and WBR elimination diet (n = 130) Controls (n = 265) | 7 yrs | Height | Low |
| Scholl et al. (2014, US) [46] | Cohort | Maternal Ca metabolic stress defined as elevated intact parathyroid hormone | Infants of pregnant women (n = 1,116): 22.8 ± 5.5 yrs | 29 yrs | Infant birth weight, risk of SGA at birth, fetal growth (birth length and head circumference) | Low |

Ca, calcium; EAR, Estimated Average Requirement; KBD, Kashin–Beck disease; SGA, small-for-gestational-age; CM, cow's milk; WBR, wheat, barley or rye; RCT, randomized controlled trial; BMI, body mass index.

1)The quality of each study is assessed on the basis of the study design, and risk of bias assessment is used for RCTs [6] cohort or cross-sectional studies [4].

2)Ca of 15 mmol and vitamin D of 625 μg were given to the study participants. The mmol unit of Ca and μg of vitamin D are converted to mg and IU in the table, respectively.
The relationship between Ca intake and growth in infants, toddlers, and adolescents were not consistent across studies (Table 4). There was no effect of Ca on growth in Tibetan children [7] and newborn [43]. However, Ca supplement was associated with an increase in adolescent growth [8], in which Ca and vitamin D supplementation had a positive effect on growth [44] and bone loss [38]. Milk consumption [45] and maternal Ca [46] were related to the growth of the fetus and children, respectively. These studies had several limitations to be considered as the evidence of EAR for Ca. Two RCTs studies were not double blinded and lacked detailed information on statistical analysis or Ca intake amount [7,44]. Three RCTs studies had a short supplementation period, and the number of the study participants was small [7,38,43]. In one study, information on key factors related to growth such as physical activity, ultraviolet rays, vitamin D, and lean body mass was unclear or did not take account in the statistical model.

### Table 5. Characteristics of the included studies examining the effect of Ca intake (EAR level) on cardiovascular diseases

| Author (Year, Country) | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|-------------|-----------------------------------------------------|------------------------------|-------------|------------------|-------------|
| Kato et al. (2018, Japan) [54] | RCT-crossover | Ca group: Ca salt of alginic acid (Ca-Alg 8%, Ca-Alg 5%) | Men and women (n = 15): 21.3 yrs | 30 min | TC LDL HDL TG | Some concerns |
| Gong et al. (2017, China) [51] | RCT-parallel | Group A: routine rope skipping for 60 min/day vs. Group B: 50 mg/kg Ca pyruvate (2 servings/day, 12 wks) vs. Group C: exercise + Ca | College women students (n = 60): 20.5 ± 1.5 yrs | 12 wks | TC LDL HDL TG | High |
| Bell et al. (2017, Canada) [52] | RCT-parallel | Supplement group: 30 g whey protein + 2.5 g creatine + 500 IU vitamin D, 400 mg Ca + 1,500 mg n-3 PUFA (with 700 mg as eicosapentaenoic acid vs. docosahexaenoic acid) vs. Placebo | Older men (n = 49): 20.5 ± 0.5 yrs | 20 wks | TC LDL HDL TG | Low |
| Cronin et al. (2016, UK) [53] | RCT-parallel | Ca group: 800 mg Ca (24 g Aquamin) vs. CaFOS group: 800 mg Ca + 3 g scFOS vs. Control (MD) | Postmenopausal women (n = 300): 61.3 ± 6.61 yrs vs. CaFOS: 61.3 ± 6.4 yrs vs. Control: 60.4 ± 6.3 yrs | 2 yrs | TC LDL HDL TG | Low |
| Hjerpested et al. (2016, Denmark) [55] | RCT-crossover | Low intake group (< 9.8 MJ): 111 g cheese, 37 g butter vs. Medium intake group (9.8–12.5 MJ): 143 g cheese, 47 g butter vs. High intake group (> 12.5 MJ): 176 g cheese, 58 g butter | Men and women: 56.7 ± 11.1 yrs | 12 wks | TC LDL HDL TG | High |
| Soerensen et al. (2014, Denmark) [49] | RCT-crossover | Milk diet group (semi-skimmed milk-based diet): 1,143 mg Ca vs. Cheese diet group (semi-hard cow-cheese-based diet): 1,172 mg Ca vs. Control diet group (nondairy diet): 362 mg Ca | Women (n = 8): 27.7 ± 4.8 yrs | 6 weeks | LDL HDL TG | Some concerns |
| Schnatz et al. (2014, US) [47] | RCT-parallel | Ca + vitamin D group: 1,000 mg Ca carbonate + 400 IU vitamin D vs. Placebo | Postmenopausal women (n = 600): 50.5 ± 7.9 yrs | 2 yrs | HDL LD TG | Low |

Cross-sectional studies

| Author (Year, Country) | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|-------------|-----------------------------------------------------|------------------------------|-------------|------------------|-------------|
| Song et al. (2016, Korea) [50] | Cross-sectional study | Compliance with the recommended food group (milk and dairy products) using the dyslipidemia pattern (TG, HDL) score | Men (n = 45), Women (n = 93): Mean age range: 56.6–58.3 yrs | End point measurement | TC LDL HDL TG | Low |
### Table 5. (Continued) Characteristics of the included studies examining the effect of Ca intake (EAR level) on cardiovascular diseases

| Author (Year, Country) | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|--------------|------------------------------------------------------|-------------------------------|--------------|------------------|-------------|
| Choi et al. (2015, Korea) [48] | Cross-sectional study | Ca Intake level | Men (n = 3,452):<br> - < 300 mg/day of Ca (n = 714): 57.4 ± 0.6 yrs<br> - 300–600 mg/day of Ca (n = 1,574): 52.7 ± 0.3 yrs<br> - 600–900 mg/day of Ca (n = 751): 51.8 ± 0.3 yrs<br> - 900–1,200 mg/day of Ca (n = 255): 51.8 ± 0.7 yrs<br> - > 1,200 mg/day of Ca (n = 158): 52.7 ± 0.9 yrs<br> Women (n = 4,357):<br> - < 300 mg/day of Ca (n = 1,618): 57.3 ± 0.4 yrs<br> - 300–600 mg/day of Ca (n = 1,807): 53.1 ± 0.3 yrs<br> - 600–900 mg/day of Ca (n = 617): 52.2 ± 0.7 yrs<br> - 900–1,200 mg/day of Ca (n = 205): 52.2 ± 0.7 yrs<br> - > 1,200 mg/day of Ca (n = 110): 53.5 ± 1.1 yrs | Postmenopausal women (n = 300):<br> Ca: 61.3 ± 6.61 yrs<br> CaFOS: 61.3 ± 6.4 yrs<br> Control: 60.4 ± 6.3 yrs | End point measurement | FRS | Low |
| Cronin et al. (2016, UK) [53] | RCT-parallel | Ca group: 800 mg Ca (24 g Aquamin) vs. CaFOS group: 800 mg Ca + 3 g scFOS vs. Control (MD) | Men (n = 3,452):<br> - < 300 mg/day of Ca (n = 714): 57.4 ± 0.6 yrs<br> - 300–600 mg/day of Ca (n = 1,574): 52.7 ± 0.3 yrs<br> - 600–900 mg/day of Ca (n = 751): 51.8 ± 0.3 yrs<br> - 900–1,200 mg/day of Ca (n = 255): 51.8 ± 0.7 yrs<br> - > 1,200 mg/day of Ca (n = 158): 52.7 ± 0.9 yrs<br> Women (n = 4,357):<br> - < 300 mg/day of Ca (n = 1,618): 57.3 ± 0.4 yrs<br> - 300–600 mg/day of Ca (n = 1,807): 53.1 ± 0.3 yrs<br> - 600–900 mg/day of Ca (n = 617): 52.2 ± 0.7 yrs<br> - 900–1,200 mg/day of Ca (n = 205): 52.2 ± 0.7 yrs<br> - > 1,200 mg/day of Ca (n = 110): 53.5 ± 1.1 yrs | Postmenopausal women (n = 300):<br> Ca: 61.3 ± 6.61 yrs<br> CaFOS: 61.3 ± 6.4 yrs<br> Control: 60.4 ± 6.3 yrs | End point measurement | FRS | Low |
| Asemi et al. (2016, Iran) [43] | RCT-parallel | Ca + vitamin D group: 500 mg of Ca + 200 IU cholecalciferol vs. Placebo | Men (n = 15):<br> Age range: 18–40 yrs<br> Women (n = 30):<br> Age range: 18–40 yrs | 9 wks | SBP, DBP | Low |
| Soerensen et al. (2014, Denmark) [49] | RCT-crossover | Milk diet group (semi-skimmed milk-based diet): 1,143 mg Ca vs. Cheese diet group (semi-hard cow-cheese-based diet): 362 mg Ca vs. Control diet group (nondairy diet): 1,172 mg Ca vs. Control diet group (nondairy diet): 362 mg Ca | Men (n = 15):<br> Age range: 18–50 yrs<br> Girls (n = 435): 12.7 ± 0.4 yrs<br> Boys (n = 453): 12.8 ± 0.5 yrs | 6 wks | SBP, DBP | Some concerns |

Ca, calcium; EAR, Estimated Average Requirement; RCT, randomized controlled trial; CaFOS, 800 mg of calcium with 3 g of short-chain fructo-oligosaccharides; scFOS, short-chain fructo-oligosaccharides; MD, maltodextrin; TC, total cholesterol; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TG, triglyceride; MJ, megajoule; PUFA, polyunsaturated fatty acid; FRS, Framingham risk score.

1) The quality of each study is assessed on the basis of the study design, and risk of bias assessment is used for RCTs [6] or cross-sectional studies [4].

### Table 6. Characteristics of the included studies examining the effect of Ca intake (EAR level) on hypertension

| Author (Year, Country) | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|--------------|------------------------------------------------------|-------------------------------|--------------|------------------|-------------|
| Cronin et al. (2016, UK) [53] | RCT-parallel | Ca group: 800 mg Ca (24 g Aquamin) vs. CaFOS group: 800 mg Ca + 3 g scFOS vs. Control (MD) | Postmenopausal women (n = 300):<br> Ca: 61.3 ± 6.61 yrs<br> CaFOS: 61.3 ± 6.4 yrs<br> Control: 60.4 ± 6.3 yrs | 2 yrs | SBP, DBP | Low |
| Asemi et al. (2016, Iran) [43] | RCT-parallel | Ca + vitamin D group: 500 mg of Ca + 200 IU cholecalciferol vs. Placebo | Iran pregnant women (n = 42):<br> Age range: 18–40 yrs | 9 wks | SBP, DBP | Low |
| Soerensen et al. (2014, Denmark) [49] | RCT-crossover | Milk diet group (semi-skimmed milk-based diet): 1,143 mg Ca vs. Cheese diet group (semi-hard cow-cheese-based diet): 362 mg Ca vs. Control diet group (nondairy diet): 1,172 mg Ca vs. Control diet group (nondairy diet): 362 mg Ca | Men (n = 15):<br> Age range: 18–50 yrs<br> Girls (n = 435): 12.7 ± 0.4 yrs<br> Boys (n = 453): 12.8 ± 0.5 yrs | 6 wks | SBP, DBP | Some concerns |

Ca, calcium; EAR, Estimated Average Requirement; RCT, randomized controlled trial; CaFOS, 800 mg of calcium with 3 g of short-chain fructo-oligosaccharides; scFOS, short-chain fructo-oligosaccharides; MD, maltodextrin; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure.

1) The quality of each study is assessed on the basis of the study design, and risk of bias assessment is used for RCTs [6] or cohort studies [4].
Table 7. Characteristics of the included studies examining the effect of Ca intake (EAR level) on obesity, diabetes, and metabolic syndrome

| Author (Year, Country) | Study design | Treatment for RCTs/ Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|--------------|--------------------------------------------------------|------------------------------|--------------|------------------|-------------|
| Gong et al. (2017, China) [51] | RCT-parallel | Group A: routine rope skipping for 60 min/day vs. Group B: 50 mg/kg Ca pyruvate (2 serving/day, 12 wks) vs. Group C: exercise + Ca | College women students (n = 60): 20.5 ± 1.5 yrs | 12 wks | Weight BMI, Body fat | High |
| | | | Age range: 19–24 yrs | | | WHR | |
| | | | Group A: 20.5 ± 1.5 yrs Group B: 20.5 ± 2.5 yrs Group C: 20.5 ± 0.5 yrs | | | TGF | |
| | | | | | | BSB | |
| | | | | | | AST | |
| Bell et al. (2017, Canada) [52] | RCT-parallel | Supplemental group: 30 g whey protein + 2.5 g creatine + 500 IU vitamin D, 400 mg Ca + 1,500 mg n-3 PUFA (with 700 mg as eicosapentanoic acid + 445 mg docosahexaenoic acid) vs. Placebo | Older men (n = 49) Supplemental group (n = 25): 71 ± 1 yrs Placebo (n = 24): 74 ± 1 yrs | 20 wks | Fat mass, % body fat WHR | Low |
| | | | | | | BMI | |
| Gonzalez et al. (2014, UK) [64] | RCT-crossover | High-Ca group (CAL): 1,400 mg of Ca vs. Control group (CON): 400 mg of Ca | Men (n = 13): 26 ± 4 yrs | 4 wks | Serum insulin Blood glucose | Low |
| | | | | | | Type 2 diabetes | |
| Soerensen et al. (2014, Denmark) [49] | RCT-crossover | Milk diet group (semi-skimmed milk-based diet): 1,143 mg Ca vs. Cheese diet group (semi-hard cow-cheese-based diet): 1,172 mg Ca vs. Control diet group (nondairy diet): 362 mg Ca | Men (n = 15): 27.7 ± 4.8 yrs Age range: 18–50 yrs | 6 wks | Blood glucose | Some concerns |
| Cohort or cross-sectional studies | | | | | | |
| Marabujo et al. (2018, Portugal) [60] | Cohort | Milk intake | Adolescents (n = 941) Girls (n = 501) Boys (n = 440) Baseline age: 13 yrs | 13 yrs | BMI | Low |
| Talaei et al. (2018, Singapore) [66] | Cohort | Dairy products intake | Men and women (n = 63,257): 55.2 ± 7.6 yrs Men (n = 27,954) Women (n = 35,303) | 12 yrs | Type 2 diabetes | Low |
| Jeon et al. (2018, Korea) [67] | Cohort | Energy-adjusted milk intake | Men and women (n = 8,574): 51.7 ± 0.1 yrs Age range: 40–69 yrs 60 yrs or older adults (n = 1,433) Men (n = 685) NSNO (n = 299): 68.4 ± 5.6 yrs SNO (n = 161): 70.5 ± 6.3 yrs NSO (n = 69): 66.7 ± 5.0 yrs SO (n = 129): 67.7 ± 5.3 yrs Women (n = 775) NSNO (n = 299): 68.7 ± 6.3 yrs SNO (n = 164): 69.4 ± 6.0 yrs NSO (n = 71): 67.1 ± 4.9 yrs SO (n = 241): 68.4 ± 5.7 yrs | 7.3 yrs | Type 2 diabetes | Low |
| Oh et al. (2015, Korea) [62] | Cross-sectional study | Ca intake among SO SNO NSO NSNO | General non-diabetic population (n = 2,774): 49.5 yrs Age range: 25–74 yrs Men and women (n = 7,569) | 10 yrs | HbA1c | Low |
| | | | MONICA (n = 1,329): 50.5 yrs Age range: 30.6–61.1 yrs MONICA: 6 yrs DCH: 5 yrs INTER99: 5 yrs | | |  | |
| Schwab et al. (2015, Germany) [63] | Cohort | Ca intake | General non-diabetic population (n = 2,774): 49.5 yrs | 10 yrs | HbA1c | Low |
| Larsen et al. (2014, Denmark) [61] | Cohort | Ca intake | General non-diabetic population (n = 2,774): 49.5 yrs | 10 yrs | HbA1c | Low | (continued to the next page)
Two studies included specific participants, such as toddlers with food allergies [45] or infants of low-income mothers in their twenties [46]. In terms of cardiovascular disease, most studies showed that Ca supplements or dairy product intakes were negatively related to blood lipids [47-54] (Table 5). However, Ca supplements used in some studies contained other nutrients, making it difficult to evaluate the effect of Ca itself on blood lipids or cardiovascular disease [47], [51]-[53]. Several studies examined the effect of Ca on blood lipids by supplementation with Ca-rich supplements, not the dietary intake [41], [47], [52]-[54]. In some RCT studies, there was no detailed information on the randomization process [51], [55]. Several cross-sectional studies could not examine the causal relationship between Ca intake and outcomes [48], [50]. One cross-sectional study had no information on drugs affecting Ca homeostasis, while one RCT study had a very short-term change (120 min) in blood lipid concentrations [54], and another RCT study examined participants with a more atherogenic lipid profile which would be more susceptible to saturated fatty acids, inducing increases in blood lipids and resulting in more-pronounced differences between diets [49].

Among studies reviewed for the relationship between Ca intake and blood pressure (Table 6), the effect of Ca intake on the decrease in blood pressure was more significant in women compared to men [49], [56]-[58]; however, there were also results that did not show significant positive effects in both women and men [43], [49], [53]. A cohort study found that the conjoint effects of serum Ca and insulin resistance at baseline on hypertension at follow-up [59].

The effects of Ca intake on obesity, diabetes, and metabolic syndrome were not consistent (Table 7). Dietary Ca intake was not related to BMI [60] or waist circumference [61]. In elderly men, dietary Ca intake was related to sarcopenic obesity [62]. Ca supplement has a positive effect on body weight [51], lean body mass [52], and glycated hemoglobin (HbA1c) [63]. However, there was no effect [64] or a negative effect [65] of Ca supplement on blood glucose and diabetes. Ca intake from some dairy products had no effect on BMI [60], but had a positive effect on diabetes [66, 67]. Among these studies, one RCT study was not double-blinded and did not have detailed information on the randomization process or Ca intake amount [51]. Another RCTs study could not evaluate the effect of Ca itself [52].

There were studies that did not consider confounding factors related to Ca intakes, such as vitamin D intakes, PTH concentrations, fat contents of dairy products, growth status, or had dietary measurement errors [60, 63, 65-67]. For several studies, the generalizability of results was limited [49, 61, 63, 64, 66]. One cross-sectional study was limited to a causal effect of Ca intake [62].

---

Table 7. (Continued) Characteristics of the included studies examining the effect of Ca intake (EAR level) on obesity, diabetes, and metabolic syndrome

| Author (Year, Country) | Study design | Treatment for RCTs/Exposure for observational studies | Participants (n) and mean age | Study length | Outcome assessed | Risk of bias |
|------------------------|-------------|------------------------------------------------------|-------------------------------|-------------|-----------------|-------------|
| Lorenzo et al. (2014, US) [65] | Cohort | Serum Ca concentration | African-Americans, Hispanics (n = 863) Non-Hispanic whites (n = 863) Non-diabetes (n = 723): 54.4 ± 0.3 yrs Diabetes (n = 140): 56.5 ± 0.7 yrs | 5.2 yrs | Type 2 diabetes | Low |

Ca, calcium; EAR, Estimated Average Requirement; RCT, randomized controlled trial; BMI, body mass index; WHR, waist-hip ratio; TSF, triceps skinfold thickness; SBS, subscapular skinfold thickness; AST, abdominal skinfold thickness; PUFA, polyunsaturated fatty acid; MONICA, Monitoring trends and determinants of Cardiovascular disease; DCH, Diet, Cancer and Health Study; SO, sarcopenic obese; SNO, sarcopenic nonobese; NSO, nonsarcopenic obese; NSNO, nonsarcopenic nonobese.

1) The quality of each study is assessed on the basis of the study design, and risk of bias assessment is used for RCTs [6] or cohort or cross-sectional studies [4].

---

[8] Two studies included specific participants, such as toddlers with food allergies [45] or infants of low-income mothers in their twenties [46].
Results of the systematic review for establishing the Ca UL

Results of individual studies from the literature assessment have been outlined in Table 8 according to health indicators in setting the Ca UL. The major health indicators reviewed in this study include kidney stones, ossification, bone health, calcinosis, hypercalcemia, and calculus.

There was no evidence on kidney stones, ossification, bone health, and calculus to consider the intake amount of Ca UL. Health indicators showing the detrimental effects of excessive Ca intake were calcinosis, hypercalcemia, hypercalcinuria, hyperparathyroidism, and urine Ca excretion. Only one RCT study in each health indicator was reviewed. Generally, studies could not separately evaluate the effect of Ca intake alone, and the generalization of the results was limited due to small sample size. Therefore, the evidence was not enough to apply the UL criteria.

DISCUSSION

We systematically reviewed literature published between 2008–2013 and 2014–2019 to assess the evidence in revising the KDRIs for Ca. Few studies of good quality were available for review. Most scientific evidence on bone health was reliable, but studies on other outcomes were weak or lacking. No balance studies or Ca absorption studies in Koreans were available in the years between 2014–2019. The changes in EAR and RNI in certain age groups were due to changes in the physical growth standards or rounding.

Habitual Ca intake of Koreans was considered in the 2020 KDRIs. The traditional Korean diet is low in Ca and change in dietary habits may be difficult. According to some revised calculations and rounding (as explained below), the EAR and RNI were subjected to increase in children and adolescents. However, the mean Ca intakes of Korean children and
adolescents are far below those in the 2015 KDRIs, and an increase in the values for the 2020 KDRIs seemed unrealistic for public nutrition programs. Therefore, we rounded down the values resulting in similar values as those in the 2015 KDRIs. We recommend increasing the KDRIs for Ca in the future when mean Ca intake increases and approaching higher recommendations becomes realistically possible. However, due to the change in reference body size of older adults in the 2020 KDRIs, the calculated EARs and RNIs slightly decreased. The values were rounded up due to the increased risk of osteoporosis and fracture in this population and the higher rate of consumption of Ca supplements. The percentages of adults that consume Ca containing supplements and of those that reach the recommended intakes increases with age in adults, possibly due to the medical prescription of Ca supplements to prevent osteoporosis. The use of supplements may be the most practical method to adhere to the KDRIs in Koreans as habitual dietary Ca intake is low [68,69]. Accordingly, the 2020 KDRI values for Ca did not change from those of 2015.

The KDRIs are established based on the assumption that other nutrients are appropriately consumed. However, in reality, the proper intake of some nutrients may be difficult to achieve. For instance, consumption of processed foods is increasing in Korea. Processed foods are generally high in sodium and phosphorus—2 nutrients that increase Ca excretion [70] when consumed in excess. Low Ca intake and high phosphorus and sodium intake can be detrimental to bone health in Koreans [12]. In particular, Korean adolescents have the highest EAR and RNI but the lowest intakes for Ca while consuming high amounts of sodium, possibly due to high intakes of processed foods [71]. This may negatively affect peak bone mass and increase the risk of osteoporosis and fracture in the later years of life. In addition, due to the decrease of outdoor social activities, increase of indoor activities, use of face masks during coronavirus disease 2019, and limited food sources of vitamin D, vitamin D deficiency may increase despite the already low vitamin D status of Koreans [72]. Low vitamin D status affects Ca metabolism and is associated with low BMD when Ca intake is also low. Therefore, appropriate intake of nutrients in addition to Ca is necessary, especially for Koreans, a population with low mean Ca intake.

As the literature search resulted in few reliable studies to revise the 2015 KDRI values, we thoroughly re-examined the basis of the previous KDRIs. The evidence of the recommendations in children and adolescents (ages 6–18 yrs) in the 2020 KDRIs were tailored to Asians as much as possible. When evidence in the Asian population was lacking but abundant in Whites within a specific age group, we used the mean of Whites and then averaged that with values in Asians in order to give more weight to Asians. In addition, for adolescents ages 12–14 and 15–18 yrs, balance studies were utilized to calculate the EAR and RNI [73,74]. Regarding post-menopausal women, a 100 mg/day Ca increment to the calculated RNIs in women aged 50 yrs and older ensure public health protections and err on the side of caution in 2015 and was thus continued in 2020. As a result, the recommendations of the 2020 KDRIs for Ca did not change, but the scientific basis of the 2015 KDRIs was revisited and improved when determined necessarily.

Future research on the effect of Ca intake on non-skeletal outcomes, such as obesity, diabetes, hypertension, and cancer, is required. Small studies suggest a potential benefit of Ca on these outcomes [49,51], but well-designed clinical trials are lacking. In pregnant and lactating women, recent evidence [38-41] in addition to those reviewed in 2015 [75-83] indicates a possible need for additional Ca intake compared to that for non-pregnant or non-lactating women. Although the development of technical devices shows that BMD may
recover after pregnancy or weaning, micro structures may remain deteriorated [84]. However, results are inconclusive, and more research must be conducted. Due to genetics, ability, and personal preferences, nutrition is not “one size fits all.” Studies have shown that the effect of Ca supplementation on bone may differ on the genotype of the VDR [39]. Our current knowledge on personalized nutrition is still developing. The US has launched Nutrition for Precision Health, powered by the All of Us research program [85].

Some research gaps specific to Koreans were additionally identified during the literature review. Despite decades of demand for clinical trials in Koreans, few have been performed. Studies on Ca balance, Ca absorption, Ca kinetics, and RCTs in diverse age groups are lacking among Koreans. To date, we were able to identify only one small balance study conducted decades ago in Korean children [86]. However, dietary pattern, nutrient intake, body weight, and height of children has drastically changed during the past decades, limiting its applicability. One balance and isotopic study were executed in the US, with a majority of participants being Korean American adolescents (specific ethnicity is not referred to in the manuscript, but the details are familiar as one author participated in the study) [87]. To our knowledge, apart from these 2 studies, most studies of the Korean population are observational, with a majority being cross-sectional. Furthermore, Ca supplement intake information is frequently omitted in observational studies. Another research gap is in pregnant adolescents, an increasing population in Korea [88]. Unlike the DRIs in North Americans, this dynamic life stage has not yet been accounted for in the KDRIs. In addition, nutrient requirements may differ between adult pregnancy and adolescent pregnancy as competition for essential nutrients between the growing adolescent and fetus may occur. A few Ca RCTs in pregnant adolescents are available in Whites but not in Koreans [38,75]. Further clinical research in Korean pregnant females, including adolescents, is needed to be incorporated in future recommendations. Furthermore, the demand for personalized nutritional information is increasing in Korea as well. The KDRIs are utilized as public health guidelines; however, personalized approaches to nutrition may affect the shaping of the future KDRIs.

To conclude, despite a comprehensive review of the recent literature, we were unable to find high quality RCTs applicable in the 2020 KDRIs for Ca. Solid scientific evidence remains inadequate to set Ca requirements for outcomes other than bone health. Clinical trials in Koreans in diverse age groups and life stages may improve the quality of future recommendations.

ACKNOWLEDGMENTS

We thank Seunghye Kim (Chonnam National University), Hangyeol Jeon (Chonnam National University), and Dong Eun Lee (Dankook University) for their assistance in the literature screening process.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Search terms used for the literature search in setting the Estimated Average Requirements of the 2020 Dietary Reference Intakes for Koreans for calcium

Click here to view
Supplementary Table 2
Search terms used for the literature search in setting the Tolerable Upper Intake Level of the 2020 Dietary Reference Intakes for Koreans for calcium

Click here to view

REFERENCES

1. O’Dell BL, Sunde RA. Handbook of Nutritionally Essential Mineral Elements. Boca Raton (FL): CRC Press; 1997.
2. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C.: National Academies Press; 2011.
3. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
4. Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesserman JJ, Egger M. Iniciativa STROBE. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Gac Sanit 2009;23:158.
5. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: University of Ottawa; 2018 [cited 2019 January 5]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
7. Rooze S, Mathieu F, Claus W, Yangzom T, Yangzom D, Goyens P, de Maertelaer V. Effect of calcium and vitamin D on growth, rickets and Kashin-Beck disease in 0- to 5-year-old children in a rural area of central Tibet. Trop Med Int Health 2016;21:768-75.
8. Ward KA, Cole TJ, Laskey MA, Ceesay M, Mendy MB, Sawo Y, Prentice A. The effect of prepubertal calcium carbonate supplementation on skeletal development in Gambian boys—a 12-year follow-up study. J Clin Endocrinol Metab 2014;99:3169-76.
9. Palacios C, Martin BR, McCabe GP, McCabe L, Peacock M, Weaver CM. Dietary calcium requirements do not differ between Mexican-American boys and girls. J Nutr 2014;144:1167-73.
10. Ma XM, Huang ZW, Yang XG, Su YX. Calcium supplementation and bone mineral accretion in Chinese adolescents aged 12-14 years: a 12-month, dose-response, randomised intervention trial. Br J Nutr 2014;112:1510-20.
11. Vogel KA, Martin BR, McCabe LD, Peacock M, Warden SJ, McCabe GP, Weaver CM. The effect of dairy intake on bone mass and body composition in early pubertal girls and boys: a randomized controlled trial. Am J Clin Nutr 2017;105:1214-29.
12. Ministry of Health and Welfare (KR); The Korean Nutrition Society. Dietary Reference Intakes for Koreans 2015. Sejong: Ministry of Health and Welfare; 2015.
13. Silk LN, Greene DA, Baker MK, Jander CB. Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: a randomised controlled trial. Bone 2015;81:554-61.
14. Aloia JF, Bojadzievski T, Yusupov E, Shahzad G, Pollack S, Mikhail M, Yeh J. The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design. J Clin Endocrinol Metab 2010;95:3216-24.
15. Reid IR, Ames R, Mason B, Reid HE, Bacon CJ, Bolland MJ, Gamble GD, Grey A, Horne A. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008;168:2276-82.

16. Mathis S, Farley RS, Fuller DK, Jetton AE, Ishikawa S, Caputo JL. Effects of a calcium supplement on bone mineral density in male cyclists. J Sports Med Phys Fitness 2015;55:940-5.

17. Gaffney-Stomberg E, Lutz LJ, Rood JC, Cable SJ, Pasiakos SM, Young AI, McClung JP. Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial. Bone 2014;68:46-56.

18. Silk LN, Greene DA, Baker MK, Jander CB. The effect of calcium and vitamin D supplementation on bone health of male Jockeys. J Sci Med Sport 2017;20:225-9.

19. Liu BX, Chen SP, Li YD, Wang J, Zhang B, Lin Y, Guan JH, Cai YF, Liang Z, Zheng F. The effect of the modified eighth section of eight-section brocade on osteoporosis in postmenopausal women: a prospective randomized trial. Medicine (Baltimore) 2015;94:e991.

20. Slevin MM, Allsopp PJ, Magee PJ, Bonham MP, Naughton VR, Strain JJ, Duffy ME, Wallace JM, Mc Sorley EM. Supplementation with calcium and short-chain fructo-oligosaccharides affects markers of bone turnover but not bone mineral density in postmenopausal women. J Nutr 2014;144:297-304.

21. Aloia JF, Dhaliwal R, Shieh A, Mikhail M, Islam S, Yeh JK. Calcium and vitamin D supplementation in postmenopausal women. J Clin Endocrinol Metab 2013;98:E1702-9.

22. Rajatanavin R, Chailurkit L, Saetung S, Thakkinstian A, Nimitphong H. The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial. Osteoporos Int 2013;24:2871-7.

23. Nakamura K, Saito T, Kobayashi R, Oshiki R, Kitamura K, Oyama M, Narisawa S, Nashimoto M, Takahashi S, Takachi R. Effect of low-dose calcium supplements on bone loss in perimenopausal and postmenopausal Asian women: a randomized controlled trial. J Bone Miner Res 2012;27:2264-70.

24. Zenk JL, Frestedt JL, Kuskowski MA. Effect of calcium derived from Lithothamnion sp. on markers of calcium metabolism in premenopausal women. J Med Food 2018;21:154-8.

25. Lee KS, Jang JS, Lee DR, Kim YH, Nam GE, Han BD, Han KD, Cho KH, Kim SM, Choi YS, et al. Serum ferritin levels are positively associated with bone mineral density in elderly Korean men: the 2008-2010 Korea National Health and Nutrition Examination Surveys. J Bone Miner Metab 2014;32:683-90.

26. Chinda D, Shimoyama T, Sawada K, Iino C, Saturaba H, Nakaji S, Fukuda S. Lifestyle factors rather than Helicobacter pylori infection or estradiol level are associated with osteopenia in Japanese men. Am J Men Health 2019;13:1557-988319848219.

27. Lee KM, Kwon SS, Chung CY, Lee SY, Kim TG, Choi Y, Park MS. Gender- and body-site-specific factors associated with bone mineral density in a non-institutionalized Korean population aged ≥50 years. J Bone Miner Metab 2015;33:401-9.

28. Lee KI, Kim KS, Kim HN, Seo JA, Song SW. Association between dietary calcium and phosphorus intakes, dietary calcium/phosphorus ratio and bone mass in the Korean population. Nutr J 2014;13:114.

29. Yang YJ, Kim J. Factors in relation to bone mineral density in Korean middle-aged and older men: 2008-2010 Korea National Health and Nutrition Examination Survey. Ann Nutr Metab 2014;64:50-9.

30. Lee JW, Choi MJ. Nutrition, food habit, and bone mineral density in young college females. Osteoporosis 2013;11:88-8.

31. Samozai MN, Kulkarni AK. Do calcium supplements increase serum and urine calcium levels in post-menopausal women? J Nutr Health Aging 2015;19:537-41.
32. Kim MK, Chon SJ, Noe EB, Roh YH, Yun BH, Cho S, Choi YS, Lee BS, Seo SK. Associations of dietary calcium intake with metabolic syndrome and bone mineral density among the Korean population: KNHANES 2008-2011. Osteoporos Int 2017;28:299-308.

33. Kim KM, Choi SH, Lim S, Moon IH, Kim JH, Kim SW, Jang HC, Shin CS. Interactions between dietary calcium intake and bone mineral density or bone geometry in a low calcium intake population (KNHANES IV 2008-2010). J Clin Endocrinol Metab 2014;99:2409-17.

34. Alghadir AH, Gabr SA, Al-Eisa E. Physical activity and lifestyle effects on bone mineral density among young adults: sociodemographic and biochemical analysis. J Phys Ther Sci 2015;27:2261-70.

35. Kim KM, Choi HS, Choi MJ, Chung HY. Calcium and vitamin D supplementations: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab 2015;22:143-9.

36. Joo NS, Dawson-Hughes B, Kim YS, Oh K, Yeum KJ. Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density: analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010). J Bone Miner Res 2013;28:764-70.

37. Uenishi K, Ishida H, Kamei A, Shiraki M, Ezawa I, Goto S, Fukuoka H, Hoso T, Orimo H. Calcium requirement estimated by balance study in elderly Japanese people. Osteoporos Int 2001;12:858-63.

38. Diogenes ME, Bezerra FF, Rezende EP, Donangelo CM. Calcium plus vitamin D supplementation during the third trimester of pregnancy in adolescents accustomed to low calcium diets does not affect infant bone mass at early lactation in a randomized controlled trial. J Nutr 2015;145:1515-23.

39. Normando P, Diogenes ME, Cabello PH, Cabello GM, Donangelo CM, Bezerra FF. Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: a randomized controlled trial. Nutrition 2016;32:1068-74.

40. Ettinger AS, Lamadrid-Figueroa H, Mercado-Garcia A, Kordas K, Wood RJ, Peterson KE, Hu H, Hernández-Avila M, Téllez-Rojo MM. Effect of calcium supplementation on bone resorption in pregnancy and the early postpartum: a randomized controlled trial in Mexican women. Nutr J 2014;13:116.

41. Cullers A, King JC, Van Loan M, Gildengorin G, Fung EB. Effect of prenatal calcium supplementation on bone during pregnancy and 1 y postpartum. Am J Clin Nutr 2019;109:197-206.

42. Zhang ZQ, Chen YM, Wang RQ, Huang ZW, Yang XG, Su YX. The effects of different levels of calcium supplementation on the bone mineral status of postpartum lactating Chinese women: a 12-month randomised, double-blinded, controlled trial. Br J Nutr 2016;115:24-31.

43. Asemi Z, Samimi M, Siavashani MA, Mazloomi M, Tabassi Z, Karamali M, Jamilian M, Esmaillzadeh A. Calcium-vitamin D co-supplementation affects metabolic profiles, but not pregnancy outcomes, in healthy pregnant women. Int J Prev Med 2016;7:49.

44. Khadilkar AV, Kadam NS, Chiplonkar SA, Khadilkar VV. Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls. J Pediatr Endocrinol Metab 2014;27:245-52.

45. Tuokkola J, Luukkainen P, Nevalainen J, Ahonen S, Toppari J, Ilonen J, Veijola R, Knip M, Virtanen SM, Kaila M. Eliminating cows' milk, but not wheat, barley or rye, increases the risk of growth deceleration and nutritional inadequacies. Acta Paediatr 2017;106:1142-9.

46. Scholl TO, Chen X, Stein TP. Maternal calcium metabolic stress and fetal growth. Am J Clin Nutr 2014;99:918-25.
and cholesterol profiles in the Women’s Health Initiative calcium/vitamin D randomized trial. Menopause 2014;21:823-33.

48. Choi SJ, Yeum KJ, Park SJ, Choi B, Joo NS. Dietary calcium and Framingham Risk Score in vitamin D deficient male (KNHANES 2009-2011). Yonsei Med J 2015;56:845-52.

49. Soerensen KV, Thorning TK, Astrup A, Kristensen M, Lorenzen JK. Effect of dairy calcium from cheese and milk on fecal fat excretion, blood lipids, and appetite in young men. Am J Clin Nutr 2014;99:984-91.

50. Song S, Paik HY, Park M, Song Y. Dyslipidemia patterns are differentially associated with dietary factors. Clin Nutr 2016;35:885-91.

51. Gong W, Jiang J. Effect of rope skipping combining calcium pyruvate on fat metabolism of female college students. Biomed Res (Aligarh) 2018;S333-6.

52. Bell KE, Snijders T, Zulyniak M, Kumbhare D, Parise G, Chabowski A, Phillips SM. A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: a randomized controlled trial. PLoS One 2017;12:e0181387.

53. Cronin BE, Allsopp PJ, Slevin MM, Magee PJ, Livingstone MB, Strain JJ, McSorley EM. Effects of supplementation with a calcium-rich marine-derived multi-mineral supplement and short-chain fructooligosaccharides on serum lipids in postmenopausal women. Br J Nutr 2016;115:658-65.

54. Kato T, Idota Y, Shiragami K, Koike M, Nishibori F, Tomokane M, Seki T, Itabashi K, Hakoda K, Takahashi H, et al. Randomized, double-blind, crossover clinical trial of the effect of calcium alginate in noodles on postprandial blood glucose level. Biol Pharm Bull 2018;41:1367-71.

55. Hjerpsted JB, Dragsted LO, Tholstrup T. Cheese intake lowers plasma cholesterol concentrations without increasing bile acid excretion. J Nutr Intermed Metab 2016;3:12-7.

56. Khanam F, Hossain B, Mistry SK, Mitra DK, Raza WA, Rifat M, Afzana K, Rahman M. The association between daily 500 mg calcium supplementation and lower pregnancy-induced hypertension risk in Bangladesh. BMC Pregnancy Childbirth 2018;18:406.

57. Liu Z, Fang A, He J, Shen X, Gao R, Zhao X, Li K. Association of habitually low intake of dietary calcium with blood pressure and hypertension in a population with predominantly plant-based diets. Nutrients 2018;10:603.

58. Gopinath B, Flood VM, Burlutsky G, Louie JC, Baur LA, Mitchell P. Dairy food consumption, blood pressure and retinal microcirculation in adolescents. Nutr Metab Cardiovasc Dis 2014;24:1221-7.

59. Wu X, Han T, Gao J, Zhang Y, Zhao S, Sun R, Sun C, Niu Y, Li Y. Association of serum calcium and insulin resistance with hypertension risk: a prospective population-based study. J Am Heart Assoc 2019;8:e009585.

60. Marabujo T, Ramos E, Lopes C. Dairy products and total calcium intake at 13 years of age and its association with obesity at 21 years of age. Eur J Clin Nutr 2018;72:541-7.

61. Larsen SC, Ångquist L, Alhewalia TS, Skagały T, Roswall N, Tjønneland A, Halkjær J, Overvad K, Pedersen O, Hansen T, et al. Interaction between genetic predisposition to obesity and dietary calcium in relation to subsequent change in body weight and waist circumference. Am J Clin Nutr 2014;99:957-65.

62. Oo C, Hoo S, No JK, Kim HS. Body composition changes were related to nutrient intakes in elderly men but elderly women had a higher prevalence of sarcopenic obesity in a population of Korean adults. Nutr Res 2015;35:1-6.

63. Schwab S, Zierer A, Heier M, Fischer B, Huth C, Baumert J, Meisinger C, Peters A, Thoroan B. Intake of vitamin and mineral supplements and longitudinal association with HbA1c levels in the general non-diabetic population—results from the MONICA/KORA S3/F3 study. PLoS One 2015;10:e0139244.
64. Gonzalez JT, Green BP, Campbell MD, Rumbold PL, Stevenson EJ. The influence of calcium supplementation on substrate metabolism during exercise in humans: a randomized controlled trial. Eur J Clin Nutr 2014;68:712-8.

65. Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 2014;57:1366-74.

66. Talaei M, Pan A, Yuan JM, Koh WP. Dairy intake and risk of type 2 diabetes. Clin Nutr 2018;37:712-8.

67. Jeon J, Jang I, Park K. Effects of consuming calcium-rich foods on the incidence of type 2 diabetes mellitus. Nutrients 2018;11:31.

68. Korea Centers for Disease Control and Prevention. Report Presentation of the Korea National Health and Nutrition Examination Survey (KNHANES) VI: 2013–2015. Sejong: Korea Centers for Disease Control and Prevention; 2015.

69. Korea Centers for Disease Control and Prevention. Report Presentation of the Korea National Health and Nutrition Examination Survey (KNHANES) VII: 2016–2017. Sejong: Korea Centers for Disease Control and Prevention; 2017.

70. Calvo MS, Moshfegh AJ, Tucker KL. Assessing the health impact of phosphorus in the food supply: issues and considerations. Adv Nutr 2014;5:104-13.

71. Kim M, Yoon J. Estimation of usual intake and assessment of nutrient intake for Korean adolescents: analysis of the 2010-2012 Korea National Health and Nutrition Examination Survey. Fam Environ Res 2017;55:385-97.

72. Park JH, Hong IY, Chung JW, Choi HS. Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 2018;97:e11032.

73. Vatanparast H, Bailey DA, Baxter-Jones AD, Whiting SJ. Calcium requirements for bone growth in Canadian boys and girls during adolescence. Br J Nutr 2010;103:575-80.

74. Wu L, Martin BR, Braun MM, Wastney ME, McCabe GP, McCabe LD, DiMeglio LA, Peacock M, Weaver CM. Calcium requirements and metabolism in Chinese-American boys and girls. J Bone Miner Res 2010;25:1842-9.

75. Diogenes ME, Bezerra FF, Rezende EP, Taveira MF, Pinhal I, Donangelo CM. Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial. Am J Clin Nutr 2013;98:82-91.

76. Ward KA, Jarjou L, Prentice A. Long-term effects of maternal calcium supplementation on childhood growth differ between males and females in a population accustomed to a low calcium intake. Bone 2017;103:31-8.

77. Abdel-Aleem H, Merialdi M, Elsnosy ED, Elsedfy GO, Abdel-Aleem MA, Villar J. The effect of calcium supplementation during pregnancy on fetal and infant growth: a nested randomized controlled trial within WHO calcium supplementation trial. J Matern Fetal Neonatal Med 2009;22:94-100.

78. Koo WW, Walters JC, Esterlitz J, Levine RJ, Bush AJ, Sibai B. Maternal calcium supplementation and fetal bone mineralization. Obstet Gynecol 1999;94:577-82.
82. Jarjou LM, Sawo Y, Goldberg GR, Laskey MA, Cole TJ, Prentice A. Unexpected long-term effects of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake: a follow-up study. Am J Clin Nutr 2013;98:723-30.

PUBMED | CROSSREF

83. Liu Z, Qiu L, Chen YM, Su YX. Effect of milk and calcium supplementation on bone density and bone turnover in pregnant Chinese women: a randomized controlled trial. Arch Gynecol Obstet 2011;283:205-11.

PUBMED | CROSSREF

84. Bjørnerem Å, Ghasem-Zadeh A, Wang X, Bui M, Walker SP, Zebaze R, Seeman E. Irreversible deterioration of cortical and trabecular microstructure associated with breastfeeding. J Bone Miner Res 2017;32:6817.

PUBMED | CROSSREF

85. National Institutes of Health (US). All of Us Research Program [Internet]. Bethesda (MD): National Institutes of Health; 2021 [cited 2021 October 7]. Available from: https://allofus.nih.gov/.

86. Lee KH, Choi IS, Oh SH. A study on intake/excretion of sodium and calcium in Korean children. Korean J Nutr 1995;28:749-58.

87. Park CY, Hill KM, Elble AE, Martin BR, DiMeglio LA, Peacock M, McCabe GP, Weaver CM. Daily supplementation with 25 μg cholecalciferol does not increase calcium absorption or skeletal retention in adolescent girls with low serum 25-hydroxyvitamin D. J Nutr 2010;140:2139-44.

PUBMED | CROSSREF

88. Shin JH, Bauer S, Yoon VS, Jeong HC, Rhie YJ, Lee JH, Woo CW, Choi BM, Kim HJ, Park SH, et al. Obstetric and neonatal outcomes of the teenage pregnancy. J Korean Soc Neonatol 2010;17:94-101.

89. Aloi JA, Katumuluwa S, Stolberg A, Usera G, Mikhail M, Hoofnagle AN, Islam S. Safety of calcium and vitamin D supplements, a randomized controlled trial. Clin Endocrinol (Oxf) 2018;89:742-9.

PUBMED | CROSSREF

90. Bristow SM, Gamble GD, Pasch A, O’Neill WC, Stewart A, Horne AM, Reid IR. Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial. Osteoporos Int 2016;27:1209-16.

PUBMED | CROSSREF

91. Harris SS, Dawson-Hughes B. Effects of hydration and calcium supplementation on urine calcium concentration in healthy postmenopausal women. J Am Coll Nutr 2015;34:340-6.

PUBMED | CROSSREF

92. Vaidya A, Cushman GC, Paik JM, Wang M, Taylor EN. Physical activity and the risk of primary hyperparathyroidism. J Clin Endocrinol Metab 2016;101:1590-7.

PUBMED | CROSSREF